Joshua H. Bilenker, President & CEO at Loxo Oncology, Inc. (LOXO), sold 9,800 shares at $164.16 ($1.6M) on 2018-09-12, disclosed to the SEC on 2018-09-14.
Open-market sale of $1.6M LOXO by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $164.16 | 700 | $115K | 7.0% |
| 2 | $165.18 | 3,700 | $611K | 37.5% |
| 3 | $166.49 | 2,400 | $400K | 24.5% |
| 4 | $167.38 | 1,800 | $301K | 18.5% |
| 5 | $168.51 | 800 | $135K | 8.3% |
| 6 | $171.08 | 400 |
| $68K |
| 4.2% |
| Total | $166.34 avg | 9,800 | $1.6M | 100% |
| Filing → |
| LOXO | SELL | 2018-12-12 | $2.7M | — | Filing → |
| LOXO | SELL | 2018-12-12 | $1.0M | — | Filing → |
| LOXO | SELL | 2018-11-28 | $1.2M | — | Filing → |